In compliance with rule 8.4 of the CADP, the CCESs file outcome summary can be found in the Canadian Anti-Doping Registry
In humans theres essentially no data on half-life, mechanism, or long-term side effects (source)
SLU-PP-332 is studied as an ERR pathway research compound with interest in exercise-mimetic signaling, mitochondrial metabolism, skeletal muscle pathway models, oxidative energy systems, and metabolic flexibility
However, there is limited research on its specific interaction with CCL11
Common problems during your first diet
Key metabolic effects include: Enhanced lipolysis through activation of fat breakdown pathways independent of growth hormone receptors Suppressed lipogenesis reducing conversion of non-fat substrates into stored fat Increased fat oxidation and energy expenditure in multiple species models No adverse effects on insulin sensitivity or glucose metabolism, unlike full-length growth hormone Independence from IGF-1 Signaling A critical distinction of AOD-9604 is its lack of IGF-1 pathway activation: No measurable changes in serum IGF-1 levels in human clinical trials Absence of growth-promoting effects on tissues No impact on blood glucose regulation or insulin resistance Avoidance of typical growth hormone side effects including edema and tissue overgrowth Metabolic Pathway Modulation Research indicates AOD-9604 influences energy metabolism through multiple mechanisms: Increased whole-body fat oxidation rates in animal models Enhanced metabolic rate without stimulant-like effects Potential modulation of uncoupling proteins in adipose tissue Effects on lipid metabolism that persist beyond plasma clearance Critical Mechanistic Gap: Despite extensive research, the primary receptor target for AOD-9604 remains unidentified
